These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 33318060)
1. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda Ramiro S; Mostard R; Landewé RB Ann Rheum Dis; 2023 Feb; 82(2):e35. PubMed ID: 33318060 [No Abstract] [Full Text] [Related]
2. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos Ramiro S; Mostard RLM; Landewé RBM Ann Rheum Dis; 2023 Jun; 82(6):e135. PubMed ID: 33903095 [No Abstract] [Full Text] [Related]
3. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis Ramiro S; Mostard RLM; Landewé RBM Ann Rheum Dis; 2023 May; 82(5):e112. PubMed ID: 33593737 [No Abstract] [Full Text] [Related]
4. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein Landewé RB; Ramiro S; Mostard RLM Ann Rheum Dis; 2023 Jul; 82(7):e154. PubMed ID: 34162596 [No Abstract] [Full Text] [Related]
5. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. Smolen JS Ann Rheum Dis; 2023 May; 82(5):e110. PubMed ID: 33658235 [No Abstract] [Full Text] [Related]
6. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. Ramiro S; Mostard RLM; Landewé RBM Ann Rheum Dis; 2023 May; 82(5):e109. PubMed ID: 33589439 [No Abstract] [Full Text] [Related]
7. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. De Santis M; Voza A; Savevski V; Badalamenti S; Cecconi M; Mantovani A; Selmi C Ann Rheum Dis; 2023 May; 82(5):e111. PubMed ID: 33593740 [No Abstract] [Full Text] [Related]
8. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Calvo-Aranda E; Cañamares-Orbis I; Novella-Navarro M; Martinez-Alcala A; Ortega de la O MDC; Escobar-Rodriguez I; Sanchez-Aranda FM Ann Rheum Dis; 2023 Feb; 82(2):e34. PubMed ID: 33318061 [No Abstract] [Full Text] [Related]
9. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Charles P Ann Rheum Dis; 2023 May; 82(5):e108. PubMed ID: 33589440 [No Abstract] [Full Text] [Related]
10. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Kaklamanos A; Karamichalos P; Vlachoyiannopoulos PG; Tzioufas AG Ann Rheum Dis; 2023 Jun; 82(6):e134. PubMed ID: 33903096 [No Abstract] [Full Text] [Related]
11. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Klopfenstein T; Gendrin V; Conrozier T; Gerazime A; Puyraveau M; Zayet S Ann Rheum Dis; 2023 Jul; 82(7):e153. PubMed ID: 34162593 [No Abstract] [Full Text] [Related]
12. COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. Landewé RBM; Ramiro S; Mostard RLM RMD Open; 2021 Mar; 7(1):. PubMed ID: 33790049 [TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187 [TBL] [Abstract][Full Text] [Related]
14. Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. Raja K; Daniel N; Morrison S; Patel R; Gerges J; Nadeem K; Chen B; Kang S; Patel M; Beggs D; Attalla M; Ballem N; Philips M J Pharm Pract; 2023 Apr; 36(2):213-220. PubMed ID: 34231415 [TBL] [Abstract][Full Text] [Related]
15. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373 [TBL] [Abstract][Full Text] [Related]
17. The shortcomings of tocilizumab in COVID-19. Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619 [TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania. Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382 [TBL] [Abstract][Full Text] [Related]
19. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors. Cure E; Kucuk A; Cure MC Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908 [TBL] [Abstract][Full Text] [Related]